AME vs STRO · P/E 30, rev $7.40B vs rev $62.0M
Ametek Inc (AME) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Ametek Inc (AME) is a specialty industrial machinery company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported AME revenue for 2025-12-31 was $7.40B. Net income was $1.48B. Revenue was up 6.6% from 2024-12-31 to 2025-12-31. AME currently screens at market cap $42.11B and trailing P/E 29.9.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
AME currently screens at market cap $42.11B and trailing P/E 29.9. STRO currently screens at market cap $470.8M.
Not investment advice. Open the AME and STRO stock pages for the full models.
Not investment advice.